Announced Mon, 26 Oct, 2026 · 18:03 IST

Epigral board to approve Q2 and half-year results on 2 November 2026

Results View source PDF Explain this filing

EPIGRAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹886.40

prior close

₹887.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-0.5% vs market

Specialty Chemicals peers, median of 100sector+1.6%-0.4% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.6

15m

+1.3

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3+1.7-0.5+1.6-0.4

Next day

+2.5pendingpending+1.9+0.7

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 100Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Epigral Limited has scheduled a board meeting for 2 November 2026 to approve the unaudited standalone and consolidated financial results for the second quarter and half-year ended 30 September 2026. The board will also record the statutory auditors' limited review report. No financial figures are provided in this notice.

Likely market impact

This is only a meeting notice. It provides no earnings or cash-flow data, so the likely immediate share-price impact is limited.